Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma

Next Previous
Trial Profile

Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oblimersen (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Pharmacodynamics; Registrational; Therapeutic Use

    • Most Recent Events

    • 07 Jun 2011 Results of an pooled exploratory analysis for PFS of this study and the AGENDA study presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jan 2011 Assessment of the late endpoints of durable response and overall survival will conclude at the end of quarter 1, 2011, with release of these data expected early Q2 2011, according to a Genta media release.
    • 07 Jun 2010 Pooled overall response and progression-free survival results of the AGENDA (700022707) and GM301 trials presented at ASCO, according to a Genta media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top